Switzerland's Controversial Kairos Collar Faces First Human Trial for Assisted Suicide

A new suicide device, the Kairos collar, is set for its first human trial in Switzerland. The neckband, designed by euthanasia activist Philip Nitschke, aims to provide a drug-free method of ending life by compressing key arteries. Legal and medical experts, however, have raised concerns over its compliance with Swiss assisted-suicide laws.

The test follows the controversial first use of Nitschke's Sarco suicide pod in September 2024, which also sparked ethical debates and police scrutiny.

The Kairos collar works by inflating balloons inside a neckband to cut off blood flow to the brain. Within seconds, the user loses consciousness, followed by death. Nitschke describes it as a major step forward—fast, reliable, and free from legal restrictions tied to prescription drugs.

A Dutch volunteer has agreed to be the first person to test the device. Swiss authorities, however, remain cautious. The country's assisted-suicide laws require third-party involvement to prevent abuse, but the collar's autonomous design could bypass this safeguard. Similar issues arose after the Sarco pod's debut, when a 64-year-old American woman with a severe illness became its first user. Investigators later examined strangulation marks on her body, raising questions about oversight.

The Kairos project is backed by The Last Resort, a Swiss euthanasia group. Marc Dusseiller, a 50-year-old Swiss national, recently joined its board to support the collar's development. Unlike the Sarco pod, which cost thousands, the collar will be priced at just a few hundred Swiss francs—enough to cover manufacturing.

Swiss law allows assisted suicide if providers act without self-interest, such as charging excessive fees. But critics argue the collar's lack of medical supervision could lead to legal challenges, mirroring past controversies over Nitschke's inventions.

The planned trial of the Kairos collar marks another milestone in Nitschke's push for accessible suicide technology. Swiss regulators must now decide whether the device aligns with existing laws or risks undermining them. The outcome could influence future debates on autonomous end-of-life methods in Europe.